search
Back to results

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

Primary Purpose

Depression

Status
Completed
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
BMS-820836
BMS-820836
BMS-820836
Placebo matching BMS-820836
BMS-820836
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression

Eligibility Criteria

20 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy Japanese subjects and Japanese patients with depression (Hamilton Rating Scale for Depression (HAM-D) ≥ 14), ages 20 to 55 years.

Exclusion Criteria:

  • Any significant acute or chronic medical illness.
  • Non-compliance, or overall not suitable as determined by the investigator.
  • History of, or current clinically significant psychiatric disorders or illnesses, substance abuse or dependence.

Sites / Locations

  • Local Institution

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Arm1: BMS-820836

Arm 2: Placebo matching BMS-820836

Arm Description

Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)

Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)

Outcomes

Primary Outcome Measures

Safety and tolerability based on medical review of adverse events & results of vital sign measurements, electrocardiogram (ECGs), physical examinations, clinical laboratory test, suicidality evaluation & Montgomery Asberg Depression Rating Scale (MADRS)

Secondary Outcome Measures

Multiple-dose pharmacokinetics parameter Maximum observed concentration (Cmax) of BMS-820836 and BMS-821007
Multiple-dose pharmacokinetics parameter Concentration at 24 h (C24) of BMS-820836 and BMS-821007
Multiple-dose pharmacokinetics parameter Time of maximum observed concentration (Tmax) of BMS-820836 and BMS-821007
Multiple-dose pharmacokinetics parameter Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-820836 and BMS-821007
Multiple-dose pharmacokinetics parameter Apparent total body clearance (CLT/F) of BMS-820836 and BMS-821007
Multiple-dose pharmacokinetics parameter accumulation index (AI) of BMS-820836 and BMS-821007
Multiple-dose pharmacokinetics parameter half-life (T-HALF) of BMS-820836 and BMS-821007
Multiple-dose pharmacokinetics parameter Molar ratio of metabolite to parent Cmax or AUC(TAU)
ECG parameters (heart rate, PR, QRS, QT, and QTcF intervals)
QTcF intervals - QT interval corrected for heart rate according to Fridericia's formula
Vital sign measures (heart rate and blood pressure) and the orthostatic changes

Full Information

First Posted
July 15, 2011
Last Updated
June 7, 2013
Sponsor
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT01396252
Brief Title
Japanese Phase 1 Multiple Ascending Dose (MAD) Study
Official Title
Randomized, Placebo-Controlled, Double-Blind, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-820836 in Healthy Japanese Subjects and Japanese Patients With Depression
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
May 2012 (Actual)
Study Completion Date
May 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-820836 in healthy Japanese subjects and Japanese patients with depression.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
57 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm1: BMS-820836
Arm Type
Experimental
Arm Description
Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
Arm Title
Arm 2: Placebo matching BMS-820836
Arm Type
Placebo Comparator
Arm Description
Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Tablets, Oral, 0.5 mg, Once daily, 14 days
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Tablets, Oral, 1 mg, Once daily, 14 days
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Tablets, Oral, 2 mg, Once daily, 14 days
Intervention Type
Drug
Intervention Name(s)
Placebo matching BMS-820836
Intervention Description
Tablets, Oral, 0 mg, Once daily, 14 days
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
Primary Outcome Measure Information:
Title
Safety and tolerability based on medical review of adverse events & results of vital sign measurements, electrocardiogram (ECGs), physical examinations, clinical laboratory test, suicidality evaluation & Montgomery Asberg Depression Rating Scale (MADRS)
Time Frame
Day 1 through Day 33
Secondary Outcome Measure Information:
Title
Multiple-dose pharmacokinetics parameter Maximum observed concentration (Cmax) of BMS-820836 and BMS-821007
Time Frame
Day1 through Day 33
Title
Multiple-dose pharmacokinetics parameter Concentration at 24 h (C24) of BMS-820836 and BMS-821007
Time Frame
Day1 through Day 33
Title
Multiple-dose pharmacokinetics parameter Time of maximum observed concentration (Tmax) of BMS-820836 and BMS-821007
Time Frame
Day1 through Day 33
Title
Multiple-dose pharmacokinetics parameter Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-820836 and BMS-821007
Time Frame
Day1 through Day 33
Title
Multiple-dose pharmacokinetics parameter Apparent total body clearance (CLT/F) of BMS-820836 and BMS-821007
Time Frame
Day1 through Day 33
Title
Multiple-dose pharmacokinetics parameter accumulation index (AI) of BMS-820836 and BMS-821007
Time Frame
Day1 through Day 33
Title
Multiple-dose pharmacokinetics parameter half-life (T-HALF) of BMS-820836 and BMS-821007
Time Frame
Day1 through Day 33
Title
Multiple-dose pharmacokinetics parameter Molar ratio of metabolite to parent Cmax or AUC(TAU)
Time Frame
Day1 through Day 33
Title
ECG parameters (heart rate, PR, QRS, QT, and QTcF intervals)
Description
QTcF intervals - QT interval corrected for heart rate according to Fridericia's formula
Time Frame
Day1 through Day 33
Title
Vital sign measures (heart rate and blood pressure) and the orthostatic changes
Time Frame
Day1 through Day 33

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy Japanese subjects and Japanese patients with depression (Hamilton Rating Scale for Depression (HAM-D) ≥ 14), ages 20 to 55 years. Exclusion Criteria: Any significant acute or chronic medical illness. Non-compliance, or overall not suitable as determined by the investigator. History of, or current clinically significant psychiatric disorders or illnesses, substance abuse or dependence.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Local Institution
City
Taito-Ku
State/Province
Tokyo
ZIP/Postal Code
1110052
Country
Japan

12. IPD Sharing Statement

Links:
URL
http://www.bms.com/studyconnect/Pages/home.aspx
Description
BMS clinical trial educational resource

Learn more about this trial

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

We'll reach out to this number within 24 hrs